Prodeon Medical Performed First Urocross Procedure
The Austin hospital procedure marks the start of a controlled commercial rollout of the prostatic urethral device.
Updated on Oct. 14, 2026 in Healthcare
Live Poll
Would you prefer a removable medical implant over a permanent one for a chronic condition?
Prodeon Medical has performed the first commercial procedure using its Urocross Expander System at The Hospital at Westlake Medical Center in Austin. The system treats urinary symptoms caused by benign prostatic hyperplasia using a non-permanent implant.
Why it matters
The device offers a potential treatment for lower urinary tract symptoms without requiring the permanent implantation of foreign materials in the body. This commercial launch follows the completion of clinical trials involving patients across the U.S. and Canada.
The Urocross system utilizes a non-permanent implant that is retrieved six months after the procedure. The underlying Expander-2 clinical trial included 240 patients across 23 testing sites.
The players
Tyler McClintock
He is the physician who performed the first commercial Urocross procedure at The Hospital at Westlake Medical Center.
Prodeon Medical
This is the medical technology company responsible for the development and commercialization of the Urocross Expander System.
The Hospital at Westlake Medical Center
This Austin-based medical facility served as the site for the first commercial deployment of the new urethral device.
The details
The procedure involves placing a temporary implant through a flexible cystoscope to remodel the obstructed prostatic urethra. Prodeon Medical is now initiating a controlled commercial release that emphasizes physician training and clinical support.
Timeline
October 14, 2026: The first commercial Urocross Expander System procedure was performed.
Market Landscape
The transition of the Urocross system from clinical trial results into commercial availability mirrors broader industry shifts toward less invasive urological treatments. This move positions Prodeon Medical to compete in the expanding sector of non-permanent medical implants.
Patients experiencing lower urinary tract symptoms may see increased availability of this temporary treatment option as physicians complete their training programs. The commercial rollout is currently focused on providing clinical support to medical providers in the Austin area.
The takeaway
The Urocross system provides a temporary alternative to permanent implants for those managing benign prostatic hyperplasia symptoms. Patients should consult with their urologists to determine if this new procedure is suitable for their specific health needs.
Further reading
For more information on medical technology developments, visit Healthcare.
Live Poll
Would you prefer a removable medical implant over a permanent one for a chronic condition?
